Shree Pacetronix Ltd

Shree Pacetronix Ltd., the Pithampur-based pacemaker manufacturer, delivered a remarkable turnaround in Q4 FY26 with net profit surging to ₹1.11 crores from a mere ₹0.06 crores in Q3 FY26—an extraordinary 1,750.00% quarter-on-quarter jump. The company, with a market capitalisation of ₹56.00 crores, saw its shares rally 6.44% to ₹147.90 following the results announcement, though the stock remains 47.77% below its 52-week high of ₹283.15.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 May 2026, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 May 2026, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 March 2026, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix Ltd, a key player in the healthcare services sector, has seen its investment rating downgraded from Hold to Sell as of 19 Feb 2026. This shift reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite strong long-term fundamentals and impressive returns over the past year, recent technical indicators and valuation metrics have prompted a more cautious stance from analysts.

Shree Pacetronix Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Shree Pacetronix Ltd, a key player in the healthcare services sector, has seen its investment rating upgraded from Sell to Hold as of 2 February 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but optimistic outlook for investors amid a challenging market environment.

Shree Pacetronix Ltd, a notable player in the Healthcare Services sector, has seen its investment rating downgraded from Hold to Sell as of 28 January 2026. This shift is primarily driven by a deterioration in technical indicators, despite the company’s robust financial performance and attractive valuation metrics. Investors are advised to carefully consider the interplay of quality, valuation, financial trends, and technical signals before making investment decisions.

Shree Pacetronix Ltd, a key player in the healthcare services sector, has seen its investment rating upgraded from Sell to Hold as of 27 January 2026. This revision reflects a combination of improved technical indicators, robust financial trends, attractive valuation metrics, and sustained quality performance. Despite a recent dip in share price, the company’s long-term fundamentals and market-beating returns underpin a more optimistic outlook for investors.

Shree Pacetronix Ltd, a key player in the Healthcare Services sector, has seen its investment rating downgraded from Hold to Sell as of 20 Jan 2026. This shift is primarily driven by a deterioration in technical indicators, despite the company’s robust financial performance and attractive valuation metrics. The downgrade reflects a nuanced assessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals.

Shree Pacetronix Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 January 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Shree Pacetronix Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 01 Nov 2025. While this rating change occurred nearly two months ago, the analysis and financial metrics presented here reflect the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Shree Pacetronix, a microcap player in the Healthcare Services sector, has experienced a revision in its market evaluation reflecting recent developments in its financial and technical parameters. This shift highlights evolving perspectives on the company’s operational quality, valuation, financial trends, and technical outlook, providing investors with a refreshed understanding of its market position.